Diagnostic screening programs help catch cancer, abnormalities or other diseases before they reach an advanced stage, saving lives and healthcare costs. Screening programs include, lung, breast, prostate, and cervical cancer, among many others.
According to new survey data, nonadherence is not for lack of concern about the disease—75% of the women surveyed reported being concerned about their breast health.
Currently, there is no standardized reporting requirement related to BACs, and ACR classifies reporting vascular calcifications on breast imaging as optional.
Accurate information relative to personal risk is crucial for improving uptake of low-dose CT (LDCT) lung cancer screening, but new data indicate that many websites' content on the topic is out of date.
How recent developments in hormonal contraceptives affect breast density is an important consideration, as an increase in density category increases cancer risk.
Prior research has shown that not only is contrast-enhanced spectral mammography comparable to CE-MRI in accuracy of loco-regional staging, but some studies have even found it to perform better.
Using risk model-based strategies to determine who should undergo low-dose CT lung cancer screening is more cost effective than current U.S. Preventive Services Task Force guidelines.
The deep learning model was trained to predict risk of lung cancer in the one to six years following completion of an LDCT scan, and it does not require clinical information relative to risk factors to do so.
The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.
GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview.
Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.